HIV-1 virion production from single inducible proviruses following T-cell activation ex vivo

Journal of Virology

Volumn 90, Issue 3, 2016, Pages 1673-1676

  Bui, John K ^a   Mellors, John W ^a   Cillo, Anthony R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS RNA;

ARTICLE; BIOASSAY; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; EX VIVO STUDY; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; RNA SYNTHESIS; T LYMPHOCYTE ACTIVATION; VIRION; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS REPLICATION; CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; PROVIRUSES; VIRION; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84958078498     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02520-15     Document Type: Article

References (25)

1. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Jr, Coffin JM, Mellors JW. 2014. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 111:7078-7083. http://dx.doi.org/10.1073/pnas.1402873111.
2. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T. 2014. Histone deacetylase inhibitor romidepsin inducesHIVexpression inCD4Tcells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10:e1004071. http://dx.doi.org/10.1371/journal.ppat.1004071.
3. Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, Siliciano JD, Siliciano RF. 2013. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 9:e1003398. http://dx.doi.org/10.1371/journal.ppat.1003398.
4. Bruner KM, Hosmane NN, Siliciano RF. 2015. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol 23:192-203. http://dx.doi.org/10.1016/j.tim.2015.01.013.
5. Althaus CL, Joos B, Perelson AS, Gunthard HF. 2014. Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells. PLoS Comput Biol 10:e1003871. http://dx.doi.org/10.1371/journal.pcbi.1003871.
6. O'Connell KA, Rabi SA, Siliciano RF, Blankson JN. 2011. CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc Natl Acad Sci U S A 108:E689-E698. http://dx.doi.org/10.1073/pnas.1108866108.
7. Chen HY, Di Mascio M, Perelson AS, Ho DD, Zhang L. 2007. Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A 104:19079-19084. http://dx.doi.org/10.1073/pnas.0707449104.
8. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, Martin MA. 1993. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 67:2182-2190.
9. Tsai WP, Conley SR, Kung HF, Garrity RR, Nara PL. 1996. Preliminary in vitro growth cycle and transmission studies of HIV-1 in an autologous primary cell assay of blood-derived macrophages and peripheral blood mononuclear cells. Virology 226:205-216. http://dx.doi.org/10.1006/viro.1996.0648.
10. Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, Fyne E, Koontz D, Coffin JM, Piatak M, Jr, Mellors JW. 2014. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J Clin Microbiol 52:3944-3951. http://dx.doi.org/10.1128/JCM.02060-14.
11. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT, Jr, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43:406-413. http://dx.doi.org/10.1128/JCM.43.1.406-413.2005.
12. Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, Mican J, Rock-Kress D, Margolick JB, Coffin JA, Mellors JW. 2008. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 22:497-501. http://dx.doi.org/10.1097/QAD.0b013e3282f29478.
13. Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li S, Rossi JJ, Zaia JA, Mellors JW. 2013. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIVrelated lymphoma. J Acquir Immune Defic Syndr 63:438-441. http://dx.doi.org/10.1097/QAI.0b013e31828e6163.
14. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
15. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM, Hughes SH. 2014. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345:179-183.
16. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM. 2014. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345:570-573.
17. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, Kuruppu J, Yazdani J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. 2004. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 78:1160-1168. http://dx.doi.org/10.1128/JVI.78.3.1160-1168.2004.
18. + T cells with stem cell-like properties. Nat Med 20:139-142. http://dx.doi.org/10.1038/nm.3445.
19. Mueller SN, Gebhardt T, Carbone FR, Heath WR. 2013. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 31: 137-161. http://dx.doi.org/10.1146/annurev-immunol-032712-095954.
20. Shan L, Yang HC, Rabi SA, Bravo HC, ShroffNS, Irizarry RA, Zhang H, Margolick JB, Siliciano JD, Siliciano RF. 2011. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol 85:5384-5393. http://dx.doi.org/10.1128/JVI.02536-10.
21. Lenasi T, Contreras X, Peterlin BM. 2008. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 4:123-133. http://dx.doi.org/10.1016/j.chom.2008.05.016.
22. Mbonye U, Karn J. 2014. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 454-455:328-339.
23. Chakraborty AK, Das J. 2010. Pairing computation with experimentation: a powerful coupling for understanding T cell signalling. Nat Rev Immunol 10:59-71. http://dx.doi.org/10.1038/nri2688.
24. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169:5538-5545. http://dx.doi.org/10.4049/jimmunol.169.10.5538.
25. Santa-Marta M, de Brito PM, Godinho-Santos A, Goncalves J. 2013. Host factors and HIV-1 replication: clinical evidence and potential therapeutic approaches. Front Immunol 4:343.